GSK downgraded at Guggenheim after Q3 sales drop
https://seekingalpha.com/news/4229872-gsk-stock-downgraded-guggenheim-post-q-3-drop?source=feed_sector_healthcare
Oct 31, 2024 - GSK (GSK) stock was downgraded by Guggenheim Securities to neutral after the company's Q3 revenue decline. Read more here.
0
Wednesday's big stock stories: What’s likely to move the market in the next trading session
https://www.cnbc.com/2024/10/29/wednesdays-big-stock-stories-whats-likely-to-move-the-market.html
Oct 29, 2024 - The Nasdaq Composite notched a fresh record on Tuesday ahead of earnings from tech's heavy hitters. Here's what CNBC is watching going into Wednesday.
0
Merck says experimental RSV treatment protected infants in trial, paving way for potential approval
https://www.cnbc.com/2024/10/17/merck-says-experimental-rsv-treatment-protected-infants-in-trial.html
Oct 18, 2024 - Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season.
0
GSK reports positive Phase 3 results for nasal drug depemokimab
https://seekingalpha.com/news/4158355-gsk-reports-positive-phase-3-results-for-nasal-drug-depemokimab?source=feed_sector_healthcare
Oct 14, 2024 - GSK (GSK) reported positive Phase 3 results for its drug depemokimab in the treatment of chronic rhinosinusitis with nasal polyps. Read more here.
0
Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday
https://www.fool.com/investing/2024/10/09/why-gsk-stock-rocketed-nearly-6-skyward-on-wednesd/?source=iedfolrf0000001
Oct 09, 2024 - In a swarm of lawsuits, the company stood accused of selling a potentially cancer-causing medication.
0
GSK stock rallies 8% on Zantac litigation settlement (update)
https://seekingalpha.com/news/4157359-gsk-stock-rallies-on-zantac-litigation-settlement?source=feed_sector_healthcare
Oct 09, 2024 - GSK (GSK) stock jumped 8% after the company said it had reached agreements to settle roughly 93% of the U.S. state court liability cases filed over its drug Zantac for up to $2.2B.
0
GSK, Pfizer seeing drop in demand for RSV vaccines: report
https://seekingalpha.com/news/4157353-gsk-pfizer-seeing-drop-in-demand-for-rsv-vaccines-report?source=feed_sector_healthcare
Oct 09, 2024 - Sales of GSK (GSK) and Pfizer’s (PFE) RSV vaccines have reportedly fallen since U.S. regulators narrowed the recommended age range and frequency for the shots. Read more here.
0
GSK, Sanofi, CSL said to win $72M U.S. bird flu vaccine contract (update)
https://seekingalpha.com/news/4156506-gsk-sanofi-csl-win-us-bird-flu-vaccine-contract?source=feed_sector_healthcare
Oct 04, 2024 - GSK (GSK), Sanofi (SNY), and CSL (CSLLY) win $72M U.S. contract to expand bird flu vaccine production amid fears of human transmission. Read more here.
0
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
https://seekingalpha.com/news/4150869-gsk-posts-trial-win-rsv-shingles-shots?source=feed_sector_healthcare
Sep 18, 2024 - GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix. Read more here.
0
GSK settles two Zantac lawsuits in California
https://seekingalpha.com/news/4150814-gsk-settles-two-zantac-lawsuits-in-california?source=feed_sector_healthcare
Sep 18, 2024 - GSK settles lawsuits in California over Zantac cancer claims without admitting wrongdoing. Read more here.
0